thomas_nest Profile Banner
Thomas Nestelberger Profile
Thomas Nestelberger

@thomas_nest

Followers
443
Following
3K
Media
45
Statuses
783

Priv. Doz. Dr. / Head of Structural Cardiology / University Hospital Basel / Switzerland

Basel, Schweiz
Joined February 2016
Don't wanna be here? Send us removal request.
@thomas_nest
Thomas Nestelberger
3 months
RT @DrDamluji: Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation: @NEJM . 🥸 Trials at #ACC25 - Dapagliglozin in….
0
130
0
@thomas_nest
Thomas Nestelberger
3 months
RT @HRS_O2Journal: Prognostic impact of atrial fibrillation in patients undergoing transcatheter aortic valve implantation, by @thomas_nest….
0
1
0
@thomas_nest
Thomas Nestelberger
4 months
RT @GreggWStone: 2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a.microaxial flow pump (Imp….
0
197
0
@thomas_nest
Thomas Nestelberger
8 months
RT @ThomPilgrim: The inflammatory pathway offers a potential therapeutic target in patients undergoing TAVR: in the Co-STAR trial treatment….
0
9
0
@thomas_nest
Thomas Nestelberger
8 months
Gamechanger!!!.
@PPibarot
Philippe Pibarot
8 months
Just presented at TCT and published in NEJM by @PhilGenereuxMD showing superiority of early TAVR in asymptomatic .severe AS. This trial will change the guidelines !
Tweet media one
Tweet media two
Tweet media three
0
0
1
@thomas_nest
Thomas Nestelberger
8 months
RT @DFCapodanno: EARLY TAVR published. Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to cl….
0
81
0
@thomas_nest
Thomas Nestelberger
10 months
RT @A_Trimaille: 🚨 POPular PAUSE trial: how to manage anticoagulation during TAVI?. 😷 869 patients with severe AS with long term OAC random….
0
8
0
@thomas_nest
Thomas Nestelberger
10 months
RT @BonanadClara: #ESC24 #ACS2_ Clinical case session. "Contenido dirigido a profesionales sanitarios” .It has been a pleasure to co-modera….
0
5
0
@thomas_nest
Thomas Nestelberger
10 months
RT @DFCapodanno: In MATTERHORN, among patients with heart failure and secondary mitral regurgitation, transcatheter edge-to-edge repair was….
0
33
0
@thomas_nest
Thomas Nestelberger
10 months
RT @A_Trimaille: 🚨 RESHAPE-HF2 trial: TEER is better than medical therapy alone in patients with heart failure and MR . 😷 505 patients with….
0
16
0
@thomas_nest
Thomas Nestelberger
11 months
Are you looking for a fellowship in clinical research and structural cardiology? Apply now and join our team! @FelixMahfoud @swissCTO @J_Boeddinghaus .
0
0
1
@thomas_nest
Thomas Nestelberger
1 year
First #TAVI Sapien S3 Ultra Resilia @UniSpitalBasel Switzerland in a challenging tortouos and horzontal aorta with a great result and a great team. @FelixMahfoud @swissCTO @J_Boeddinghaus Christoph Kaiser, Yves Bayard, Mohamed Bayoumi
Tweet media one
Tweet media two
0
2
9
@thomas_nest
Thomas Nestelberger
1 year
RT @NEJM: A randomized trial that enrolled pts with severe aortic stenosis at low or intermediate surgical risk showed that transcatheter a….
0
62
0
@thomas_nest
Thomas Nestelberger
1 year
Congratulations to this amazing work. Real world data showing great outcomes for TAVI patients in comparison with SAVR!!.
@RTwerenbold
Raphael Twerenbold, MD
1 year
🚨Most excited about the results of our industry-independent DEDICATE trial presented by @MoritzSeiffert at #ACC24 and @NEJM, impressively demonstrating non-inferior safety of #TAVI versus #SAVR in lower risk patients. ❤️‍🩹@dzhk_germany @UCCS_HH @UKEHamburg.
0
0
4
@thomas_nest
Thomas Nestelberger
1 year
RT @NEJM: Presented at #ACC24:. Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label l….
0
319
0
@thomas_nest
Thomas Nestelberger
1 year
RT @NEJM: In the SMART trial of TAVR in patients with a small aortic annulus, a self-expanding valve was noninferior to a balloon-expandabl….
0
60
0
@thomas_nest
Thomas Nestelberger
1 year
RT @NEJM: Presented today at #ACC24: . In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months….
0
314
0
@thomas_nest
Thomas Nestelberger
1 year
RT @ehj_ed: Shortening in-hospital stay after transcatheter aortic valve implantation: a déjà vu in percutaneous interventions. Read the la….
0
16
0
@thomas_nest
Thomas Nestelberger
1 year
RT @swissCTO: SAVE THE DATE - SWISS CTO&CHIP
Tweet media one
0
9
0
@thomas_nest
Thomas Nestelberger
2 years
RT @guilbon: !!!NEWSFLASH!!! Long-term outcomes of the TAVI low risk trials. #PCRLV .🎯 The SAPIEN 3 and EVOLUT Low Risk trials offer an opt….
0
12
0